GLP-1 drugs made for cats are being studied in pet cats right now. Versions for dogs are in lab tests. Each one still has to pass FDA review before a vet can prescribe it.
Get an email when the first pet GLP-1 is approved
Free. We email when there is real news: a study result, an FDA decision or a drug going on sale.
Cats are closest.
Two drugs are being studied in pet cats. OKV-119 is a small implant placed under the skin. AKS-562c is a weekly shot. For now, both are given only to cats enrolled in studies.
GLP-1 for cats: see the studiesDogs are at the lab stage.
Akston has named two drugs for dogs, AKS-724d and AKS-725d. Both are being tested in mice. The next step would be a study in dogs, and we will post it here when one is announced.
GLP-1 for dogs: see what existsSource: Akston's filing with the SECOnly with your vet's guidance.
Ozempic and Wegovy are approved for people. The right dose for a dog or a cat has never been studied, so this is a decision to make with your veterinarian. Do not give your pet a human GLP-1 drug without your veterinarian's guidance.
FDA rules do let a vet prescribe some human drugs for animals in certain cases. That call belongs to your vet.
The next study result is expected in the second half of 2026.
That date is an estimate. After its studies, each drug goes to the FDA for review, and a vet can prescribe it once the FDA approves it. This is how far each one has come.
FDA approved
The FDA says yes, and vets can prescribe it.
Still ahead
With the FDA
The company sends its results in for review.
Still ahead
These dates are estimates until the companies confirm them. Latest news, August 7, 2026: The implant platform behind the cat trial just finished dosing its first humans
The main study, meant to support FDA approval
Dosing. The MEOW-1 study is running in client-owned overweight and obese cats under an FDA-CVM Investigational New Animal Drug application, with weight and health metrics measured at three and six months. CNBC reported on 18 July 2026 that top-line results of both feline GLP-1 trials are expected later this year. That sentence is unattributed, covers the two programmes in one clause, and gives no Okava-specific date; Okava itself has stated no readout date. It is recorded here because readers arrive carrying it, and it is not adopted as the MEOW-1 window: the estimate below follows the trial's own clock, a December 2025 start, an implant releasing for up to six months, a three-month primary period with an optional three-month extension, and cats still being dosed in mid-2026.
Early study, small numbers
The Cornell study in client-owned overweight cats, 70 enrolled with an option to extend, has published nothing. Cornell's own award record puts the project period at July 2025 to June 2026 and describes an 11-week treatment period, principal investigator Patrick Carney. The funded period has therefore closed without a published result. The safety data Akston presented at the 2026 ACVIM Forum came from a separate preclinical study in 16 healthy research cats: well tolerated over 12 weeks, no treatment-related toxicity, no antidrug antibodies. Those are two different cohorts and only the second has read out.
Lab tests, not yet tried in pets
Akston's 2026 SEC S-1/A names both canine candidates and says they are being tested in mice. Candidates with promising results may advance to pharmacokinetic and safety testing in laboratory dogs. Akston also states that it has not engaged regulators about these programmes. No canine clinical trial or commercial timeline has been announced.
Tracked as regulatory and historical context
Two of three FDA technical sections accepted: reasonable expectation of effectiveness in February 2025 and target animal safety in January 2026. The manufacturing section remains outstanding.
The first and so far only FDA-approved canine weight-loss drug. Approved 2007, voluntarily discontinued in 2013.
| Drug | Species | Result expected | Status | Detail |
|---|---|---|---|---|
| Pivotal studyThe main study, meant to support FDA approval | ||||
| OKV-119Okava PharmaceuticalsMEOW-1 study | Cats | summer 2027Estimate, not confirmed by the company | Dosing. The MEOW-1 study is running in client-owned overweight and obese cats under an FDA-CVM Investigational New Animal Drug application, with weight and health metrics measured at three and six months. CNBC reported on 18 July 2026 that top-line results of both feline GLP-1 trials are expected later this year. That sentence is unattributed, covers the two programmes in one clause, and gives no Okava-specific date; Okava itself has stated no readout date. It is recorded here because readers arrive carrying it, and it is not adopted as the MEOW-1 window: the estimate below follows the trial's own clock, a December 2025 start, an implant releasing for up to six months, a three-month primary period with an optional three-month extension, and cats still being dosed in mid-2026. | Full statusFull status for OKV-119 |
| Pilot studyEarly study, small numbers | ||||
| AKS-562cAkston Biosciences | Cats | second half of 2026Estimate, not confirmed by the company | The Cornell study in client-owned overweight cats, 70 enrolled with an option to extend, has published nothing. Cornell's own award record puts the project period at July 2025 to June 2026 and describes an 11-week treatment period, principal investigator Patrick Carney. The funded period has therefore closed without a published result. The safety data Akston presented at the 2026 ACVIM Forum came from a separate preclinical study in 16 healthy research cats: well tolerated over 12 weeks, no treatment-related toxicity, no antidrug antibodies. Those are two different cohorts and only the second has read out. | Full statusFull status for AKS-562c |
| PreclinicalLab tests, not yet tried in pets | ||||
| AKS-724d / AKS-725dAkston Biosciences | Dogs | Not applicable | Akston's 2026 SEC S-1/A names both canine candidates and says they are being tested in mice. Candidates with promising results may advance to pharmacokinetic and safety testing in laboratory dogs. Akston also states that it has not engaged regulators about these programmes. No canine clinical trial or commercial timeline has been announced. | Full statusFull status for AKS-724d / AKS-725d |
| Not GLP-1sTracked as regulatory and historical context | ||||
| LOY-002LoyalNot a GLP-1 | Dogs | Company-projected launch before end of 2026Estimate, not confirmed by the company | Two of three FDA technical sections accepted: reasonable expectation of effectiveness in February 2025 and target animal safety in January 2026. The manufacturing section remains outstanding. | Full statusFull status for LOY-002 |
| Slentrol (dirlotapide)Pfizer Animal HealthNot a GLP-1 | Dogs | Not applicable | The first and so far only FDA-approved canine weight-loss drug. Approved 2007, voluntarily discontinued in 2013. | Full statusFull status for Slentrol (dirlotapide) |
Nothing in this table is FDA-approved for weight loss in cats or dogs. A drug being in a pivotal study is not an approval, and an expected date is not a result. Dates marked “estimated” come from news reports or our own analysis, not from the company.
Start with the food bowl.
Check your pet's body shape first. Then turn the calorie target from your veterinarian into daily food portions. The tools are free, and you can use them right away.
Join the list. We email when there is real news, and we keep it rare.